Autoimmune Diseases
Conference Coverage
Novel oral orphan drug tames pemphigus
The Bruton tyrosine kinase inhibitor is also under study for other autoimmune diseases.
Conference Coverage
Nonadherence to lupus drugs may play a role in frequent hospitalization
SAN DIEGO – A higher risk for hospitalization also occurred among young, male, and African-American patients.
Conference Coverage
Blisibimod shows mixed results for lupus in phase 3 trial
SAN DIEGO – The drug did not meet its primary endpoint but was associated with steroid sparing, decreased urine protein, and improved biomarker...
Conference Coverage
Anabasum shows promise in treating skin-predominant dermatomyositis, systemic sclerosis
SAN DIEGO – The investigational drug met primary endpoints and showed good safety in two phase 2 studies.
Conference Coverage
Race may transcend social, geographical parameters in lupus mortality
SAN DIEGO – SLE mortality parameters did not vary among socially advantaged and disadvantaged black Americans.
Conference Coverage
Obesity linked to pain, fatigue in SLE
SAN DIEGO – The lupus study suggests there is value to assessing body mass index in these patients.
Conference Coverage
VIDEO: A challenging case of lichen planus
Think outside the box when treating difficult cases of lichen planus, lupus, and bullous pemphigoid.
From the Journals
Study highlights disparities in U.S. lupus mortality
Sex, race, and geographic region were independent risk factors for SLE mortality.
Guidelines
British Society of Rheumatology issues first U.K. lupus guideline
The guidelines are the first from any medical society for systemic lupus erythematosus overall since 2008.
From the Journals
Abatacept shows potential in refractory myositis
A small phase 2b trial provides evidence to warrant further study.
From the Journals
Poverty affects lupus mortality through damage accumulation
The study accounted for many confounding factors to determine the driving force behind elevated mortality in lupus patients who are poor.